Research Areas

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallen-Group, Fixed-Dose Study Evaluating the Effect of One Dose of An Investigational Medication (20 mg/day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled with Insulin

A randomized, double-blinded, placebo-controlled, five parallel group study investigating the efficacy and safety of an investigational medication (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks in drug naïve and treated patients with Type 2 diabetes with insufficient glycemic control ( study includes an open-label metformin treatment arm)

An Efficacy and Tolerability study An Investigational Medication in Patients with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multi-dose Study of an Investigational Medication in Type I Diabetes Mellitus Patients

A Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Effects of an Investigational Medication on Glycemic Control as Determined by Glycated Hemoglobin in Type I Diabetes Mellitus Patients

A 28 Week, Multicenter, Controlled, Randomized, Open Clinical Trial Comparing an Investigational Medication with NPH Insulin in Type I Diabetes Mellitus Patients

16-Week Multicenter, Controlled, Randomized, Open-Label Clinical Trial Comparing an Investigational Medication and NPH Human Insulin in Subjects with Type I Diabetes Treated with Insulin Lispro

Inhaled Mealtime Insulin With the AERx®iDMS Versus Subcutaneous Injected Insulin Aspart Both In Combination With Insulin Detemir in Type 1 Diabetes: A 104-Week, Open-Label, Multicenter, Randomized, parallel Trial (Followed by a Twelve-Week Re-Randomized Extension) To Investigate Safety and Efficacy

Pulmonary Outcomes within a 2-year period in Subjects with Diabetes Mellitus Treated with Technosphere®/Insulin or Usual Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control

A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of an Investigational Medication in the Treatment of Panic Disorder

Effect on Weight Loss of An Approved Medication vs. Placebo in Subjects with Type 2 Diabetes Participating in a Lifestyle Modification Program.

Study to Assess the Efficacy and Tolerability of An Investigational Medication in Maintaining Weight Loss Induced by Diet in Obese Patients

A 1-Year, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of An Investigational Medication in the Treatment of Overweight, Oral Agent-Treated Subjects with Type 2 Diabetes Mellitus.

A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of An Investigational Medication in the Treatment of Obese Subjects.

A Phase II, Randomized, Double-Blinded, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20 mg, 40 mg and 80 mg of An Investigational Medication in Patients with Mild to Moderate Diabetic Polyneuropathy

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter study Evaluating the Efficacy and Safety of Three Doses of an Investigational Medication in Abdominally Obese Patients with Atherogenic Dyslipidemia.

A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Dose-Ranging Study of an Investigational Medication in the Treatment of Mild to Moderate Hypertension

A 12 week, Multicenter, Double-Blind, Parallel, Positive-Controlled, Dose-Titration Study of an Investigational Medication Compared to Enalapril in Patients with Severe Systolic Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Nine Week Study of an Investigational Medication in the Treatment of Mild to Moderate Hypertension

An 8-week, multicenter, randomized, double-blinded, parallel-group study to evaluate the efficacy and safety of the combination of Valsartan/HCTZ/Amlodipine compared to Valsartan/HCTZ Valsartan/Amlodipine and HCTZ/Amlodipine in patients with moderate to severe hypertension